Clinical Trials Browser

Interventional × Fallopian Tube Neoplasms × rilotumumab × Clear all

NCT01039207 2017-09-07

Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Phase 2 Completed

31 enrolled 12 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms